Literature DB >> 15031788

HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load.

Annette Oxenius1, David A Price, Martin Hersberger, Erika Schlaepfer, Rainer Weber, Markus Weber, Thomas M Kundig, Jürg Böni, Helen Joller, Rodney E Phillips, Markus Flepp, Milos Opravil, Roberto F Speck.   

Abstract

The average time between infection with human immunodeficiency virus (HIV) and development of acquired immune deficiency syndrome is approximately 8 years. However, progression rates vary widely, depending on several determinants, including HIV-specific immunity, host genetic factors, and virulence of the infecting strain. In untreated HIV-infected patients with different progression rates, we examined HIV-specific T cell responses in combination with host genetic markers, such as chemokine/chemokine-receptor (CCR) polymorphisms and human leukocyte antigen (HLA) genotypes. HIV-specific CD4(+) T cell responses and, to a lesser extent, HIV-specific CD8(+) T cell responses were inversely correlated with progression rate. Slower progression was not related to polymorphisms in CCR genes, HLA genotype, or GB virus C coinfection. These data suggest that HIV-specific T cell responses are involved in protecting the host from disease progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15031788     DOI: 10.1086/382028

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response.

Authors:  Christof Geldmacher; Ian S Metzler; Sodsai Tovanabutra; Tedi E Asher; Emma Gostick; David R Ambrozak; Constantinos Petrovas; Alexandra Schuetz; Njabulo Ngwenyama; Gustavo Kijak; Leonard Maboko; Michael Hoelscher; Francine McCutchan; David A Price; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2009-06-19       Impact factor: 22.113

2.  Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.

Authors:  Bin Li; Adrianne D Gladden; Marcus Altfeld; John M Kaldor; David A Cooper; Anthony D Kelleher; Todd M Allen
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

3.  Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline.

Authors:  Yoav Peretz; Galit Alter; Marie-Pierre Boisvert; George Hatzakis; Christos M Tsoukas; Nicole F Bernard
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice.

Authors:  Stefan Baenziger; Roxane Tussiwand; Erika Schlaepfer; Luca Mazzucchelli; Mathias Heikenwalder; Michael O Kurrer; Silvia Behnke; Joachim Frey; Annette Oxenius; Helen Joller; Adriano Aguzzi; Markus G Manz; Roberto F Speck
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-12       Impact factor: 11.205

5.  Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients.

Authors:  G Harcourt; E Gomperts; S Donfield; P Klenerman
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

6.  Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo.

Authors:  Jason M Brenchley; Laura E Ruff; Joseph P Casazza; Richard A Koup; David A Price; Daniel C Douek
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Response to First-Line Antiretroviral Therapy Among PLHIV from a High-Risk, Low-Prevalence Setting.

Authors:  Shahria Mohammad Rashed Ul Islam; Munira Jahan; Afzalun Nessa; Shahina Tabassum
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

8.  Predictors of disease progression in HIV infection: a review.

Authors:  Simone E Langford; Jintanat Ananworanich; David A Cooper
Journal:  AIDS Res Ther       Date:  2007-05-14       Impact factor: 2.250

9.  Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak.

Authors:  Michael Har-Noy; Reuven Or
Journal:  J Transl Med       Date:  2020-05-12       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.